NBE-Therapeutics Appoints Bertrand Damour as Chief Executive Officer

  • 20 Years’ Industry Experience Managing Biotech Companies in US and Europe
  • Aim to Maximize Potential of ADC Platform and Accelerate Clinical Development of Lead Compound an Anti-ROR1 Antibody Drug Conjugate

Basel, Switzerland, August 3rd, 2020:  NBE-Therapeutics, the Swiss-based company developing best in class cancer therapies based on its proprietary, highly differentiated Antibody Drug Conjugate (ADC) platform, announces the appointment of Bertrand Damour as Chief Executive Officer.

Read more….

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...